La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Molecular Partners a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Molecular Partners..

Molecular Partners (NASDAQ:MOLN) Azioni, Catena delle Opzioni

Molecular Partners

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG - American Depositary Shares

Molecular Partners AG

Earnings

Press Releases

Molecular Partners Reports Financial Results and Highlights from Q1 2025

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

News

Health Care

General

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Management

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

MOLN

Abeona Therapeutics

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Anika Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Cardiff Oncology

Elicio Therapeutics

Entera Bio

Forte Biosciences

Genfit

Genelux

Heron Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Nkarta

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Comments

Molecular Partners

Molecular Partners (MOLN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO